Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada.
Blood. 2013 Aug 15;122(7):1256-65. doi: 10.1182/blood-2013-02-483727. Epub 2013 May 22.
Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous cancer composed of at least 2 molecular subtypes that differ in gene expression and distribution of mutations. Recently, application of genome/exome sequencing and RNA-seq to DLBCL has revealed numerous genes that are recurrent targets of somatic point mutation in this disease. Here we provide a whole-genome-sequencing-based perspective of DLBCL mutational complexity by characterizing 40 de novo DLBCL cases and 13 DLBCL cell lines and combining these data with DNA copy number analysis and RNA-seq from an extended cohort of 96 cases. Our analysis identified widespread genomic rearrangements including evidence for chromothripsis as well as the presence of known and novel fusion transcripts. We uncovered new gene targets of recurrent somatic point mutations and genes that are targeted by focal somatic deletions in this disease. We highlight the recurrence of germinal center B-cell-restricted mutations affecting genes that encode the S1P receptor and 2 small GTPases (GNA13 and GNAI2) that together converge on regulation of B-cell homing. We further analyzed our data to approximate the relative temporal order in which some recurrent mutations were acquired and demonstrate that ongoing acquisition of mutations and intratumoral clonal heterogeneity are common features of DLBCL. This study further improves our understanding of the processes and pathways involved in lymphomagenesis, and some of the pathways mutated here may indicate new avenues for therapeutic intervention.
弥漫性大 B 细胞淋巴瘤(DLBCL)是一种遗传异质性癌症,由至少 2 种分子亚型组成,这些亚型在基因表达和突变分布上存在差异。最近,应用基因组/外显子测序和 RNA-seq 技术对 DLBCL 的研究揭示了许多在该疾病中经常发生体细胞点突变的基因。在这里,我们通过对 40 例新诊断的 DLBCL 病例和 13 例 DLBCL 细胞系进行全基因组测序,并结合来自 96 例扩展队列的 DNA 拷贝数分析和 RNA-seq 数据,提供了基于全基因组测序的 DLBCL 突变复杂性的视角。我们的分析确定了广泛的基因组重排,包括证据表明存在染色体重排和已知和新的融合转录本。我们发现了新的体细胞点突变的靶基因和疾病中受局灶性体细胞缺失靶向的基因。我们强调了影响编码 S1P 受体和 2 种小 GTPase(GNA13 和 GNAI2)的生发中心 B 细胞受限突变的反复出现,这些突变共同作用于 B 细胞归巢的调节。我们进一步分析了我们的数据,以近似某些反复出现的突变获得的相对时间顺序,并证明持续获得突变和肿瘤内克隆异质性是 DLBCL 的共同特征。这项研究进一步提高了我们对淋巴瘤发生过程和途径的理解,其中一些突变的途径可能表明新的治疗干预途径。